Launch of a New Protein A Chromatography Resin with enhanced Binding Capacity for the Purification of Antibody Drugs

Kaneka Corporation on January 11, 2017 (Osaka, Japan, President: Mamoru Kadokura) announces the launch of “KANEKA KanCapA™ 3G”, a new protein A chromatography resin for the purification of therapeutic antibodies. KANEKA KanCapA™ 3G exhibits a 50% higher static binding capacity than our standard product. KANEKA KanCapA™ 3G is expected to reduce the production cost and improve the productivity of manufacturing processes for therapeutic antibodies.

Therapeutic antibodies are being developed as therapeutic agents to treat a wide range of diseases such as rheumatoid arthritis and cancer. As a result of this market expansion, further improvements in the productivity and production cost of these products has been expected.
Protein A chromatography resin is widely used for the purification of therapeutic antibodies due to its high affinity and excellent selectivity. Increases in upstream production titers has put pressure on the downstream processing area and led to the demand for materials with increased efficiency.

Kaneka has been selling protein A chromatography resin (product name: KANEKA KanCapA™) developed by our proprietary technology since 2012 and KANEKA KanCapA™ is already used by several pharmaceutical companies. By the ligand improvement using protein design technology, KANEKA KanCapA™ 3G was developed with approximately 50% increased binding capacity compared with our standard product. As its result, KANEKA KanCapA™ 3G is expected to show an improvement in the processing time, impurity removal and overall process efficiency of the downstream process.

Kaneka is committed to continuously expand our product portfolio to introduce optimal purification methods for therapeutic antibodies and innovative biopharmaceutical products.